IDEAYA Biosciences, Inc. current report, 07 July 2021

Full document

Business Context and Reporting Period

This Form 8-K filing by IDEAYA Biosciences, Inc. (IDYA) reports a current event dated July 7, 2021, with the transaction closing on July 12, 2021. The company, an emerging growth company incorporated in Delaware, entered into an underwriting agreement to conduct a public offering of its common stock.

Key Financial Metrics

  • Offering Size: The company sold an aggregate of 5,333,333 shares of Common Stock, including the full exercise of the underwriters' option.
  • Public Offering Price: $17.25 per share.
  • Net Proceeds: Approximately $86.1 million after deducting underwriters' discounts, commissions, and estimated offering expenses.
  • Underwriters: J.P. Morgan Securities LLC, Citigroup Global Markets Inc., and Jefferies LLC.

Material Changes

The primary material change is the increase in the company's cash liquidity resulting from the completed equity offering. The filing does not provide comparative financial data (revenue, profit, or margins) as this is a current report regarding a capital raise rather than a periodic financial statement.

Outlook, Risks, and Contingencies

  • Lock-Up Agreement: The Company, its directors, executive officers, and one affiliated holder agreed not to sell or transfer any Common Stock for 60 days following the date of the Prospectus without written consent from the underwriters.
  • Indemnification: The Company agreed to indemnify the underwriters against certain liabilities under the Securities Act of 1933.
  • Use of Proceeds: The filing text does not specify the intended use of the net proceeds.

Investor Verification Checklist

  • Verify the final closing date and total share count (5,333,333 shares) in the company's subsequent press release or 10-Q.
  • Review the prospectus supplement (Registration No. 333-254606) for the specific allocation of the $86.1 million net proceeds.
  • Confirm the expiration date of the 60-day lock-up period for insiders.
  • Check for any subsequent filings regarding the exercise of the underwriters' option, which was fully exercised in this instance.